Anti-tumour necrosis factor-alpha antibody oral

Drug Profile

Anti-tumour necrosis factor-alpha antibody oral

Alternative Names: Anti-TNF-alpha antibody oral; Arthrofoon; Artrofoon

Latest Information Update: 31 May 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Materia Medica Holding Research and Production Company
  • Developer Materia Medica Holdings
  • Class Antibodies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 28 Jun 2007 Data presented at the Annual European Congress of Rheumatology (EULAR-2007) added to the adverse events and Rheumatic Disease therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top